Drug discovery and development has become longer and costlier process.The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards“me too”drugs and improved generics(505(b)...Drug discovery and development has become longer and costlier process.The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards“me too”drugs and improved generics(505(b)(2))fillings.The discontinuance of molecules at late stage clinical trials is common these years.The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties,lack of efficacy and safety reasons.Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability.The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.展开更多
文摘Drug discovery and development has become longer and costlier process.The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards“me too”drugs and improved generics(505(b)(2))fillings.The discontinuance of molecules at late stage clinical trials is common these years.The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties,lack of efficacy and safety reasons.Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability.The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.
